Gender-specific differences in the urinary expression of aldosterone, IL-1α and IL-1β

Biomarkers in Medicine

Volumn 4, Issue 6, 2010, Pages 843-847

  Bourgeois, Marie M ^a   Richards, Ira S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

aldosterone; biomarker expression; IL 1a; IL 1b; inflammation; myeloperoxidase; oxidative stress; urine

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MYELOPEROXIDASE;

ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MALE; NON INVASIVE MEASUREMENT; NORMAL VALUE; OXIDATIVE STRESS; PILOT STUDY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SEX DIFFERENCE; URINALYSIS;

ALDOSTERONE; C-REACTIVE PROTEIN; CREATININE; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MALE; PEROXIDASE; PROTEINURIA; REFERENCE VALUES; SEX CHARACTERISTICS;

EID: 78650740092     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.102     Document Type: Article

References (49)

1. Committee on Understanding the Biology of Sex and Gender Differences, Board on Health Sciences Policy: Exploring the Biological Contributions to Human Health: Does Sex Matter? Wizemann T, Pardue M (Eds). National Academies Press, Washington, DC, USA, 288, (2001).
2. Berkley KJ, Zalcman SS, Simon VR: Sex and gender differences in pain and infammation: a rapidly maturing feld. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R241-R244 (2006).
3. Arain FA, Kuniyoshi FH, Abdalrhim AD, Miller VM: Sex/gender medicine. The biological basis for personalized care in cardiovascular medicine. Circ. J. 73, 1774-1782 (2009).
4. Hutchens MP, Dunlap J, Hurn PD, Jarnberg PO: Renal ischemia: does sex matter? Anesth. Analg. 107, 239-249 (2008).
5. McCarthy M: The "gender gap" in autoimmune disease. Lancet 356(9235), 1088 (2000).
6. Olafsdottir IS, Gislason T, Thjodleifsson B et al.: Gender differences in the association between C-reactive protein, lung function impairment, and COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2, 635-642 (2007).
7. Perucca J, Bouby N, Valeix P, Bankir L: Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R700-R705 (2007).
8. Spitzer JA: Gender differences in some host defense mechanisms. Lupus 8, 380-383 (1999).
9. Murphy E, Steenbergen C: Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 75, 478-486 (2007).
10. Ostadal B, Netuka I, Maly J, Besik J, Ostadalova I: Gender differences in cardiac ischemic injury and protection - experimental aspects. Exp. Biol. Med. (Maywood) 234, 1011-1019 (2009).
11. Liu PY, Death AK, Handelsman DJ: Androgens and cardiovascular disease. Endocr. Rev. 24, 313-340 (2003).
12. Quyyumi AA: Women and ischemic heart disease: pathophysiologic implications from the Women's Ischemia Syndrome Evaluation (WISE) Study and future research steps. J. Am. Coll. Cardiol. 47, S66-S71 (2006).
13. Devarajan P: Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin. Med. Diagn. 2, 387-398 (2008). (Pubitemid 351659225)
14. Pontremoli R, Leoncini G, Ravera M et al.: Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J. Am. Soc. Nephrol. 13(Suppl. 3), S169-S172 (2002). (Pubitemid 35216019)
15. Kang AK, Miller JA: Impact of gender on renal disease: the role of the renin angiotensin system. Clin. Invest. Med. 26, 38-44 (2003).
16. Maric C, Sullivan S: Estrogens and the diabetic kidney. Gend. Med. 5(Suppl. A) S103-S113 (2008).
17. Sandberg K: Mechanisms underlying sex differences in progressive renal disease. Gend. Med. 5, 10-23 (2008).
18. Seliger SL, Davis C, Stehman-Breen C: Gender and the progression of renal disease. Curr. Opin. Nephrol. Hypertens. 10, 219-225 (2001).
19. Silbiger SR, Neugarten J: The impact of gender on the progression of chronic renal disease. Am. J. Kidney Dis. 25, 515-533 (1995).
20. Jacobson DL, Gange SJ, Rose NR, Graham NMH: Epidemiology and estimated population burden of selected autoimmune disease in the United States. Clin. Immunol. Immunopathol. 84, 223-243 (1997).
21. Nanda N, Bobby Z, Hamide A: Oxidative stress and protein glycation in primary hypothyroidism. Male/female difference. Clin. Exp. Med. 8, 101-108 (2008).
22. Kerksick C, Taylor LT, Harvey A, Willoughby D: Gender-related differences in muscle injury, oxidative stress, and apoptosis. Med. Sci. Sports Exerc. 40, 1772-1780 (2008).
23. Nguyen VH, McLaughlin MA: Coronary artery disease in women: a review of emerging cardiovascular risk factors. Mt Sinai J. Med. 69, 338-349 (2002).
24. Fearon IM, Faux SP: Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J. Mol. Cell Cardiol. 47, 372-381 (2009).
25. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104, 2673-2678 (2001).
26. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinfammation on cardiovascular risk in patients with minor renal dysfunction. J. Am. Soc. Nephrol. 15, 538-548 (2004).
27. Loscalzo J: Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol. Haemost. Thromb. 32, 359-360 (2002).
28. Miller AA, De Silva TM, Jackman KA, Sobey CG: Effect of gender and sex hormones on vascular oxidative stress. Clin. Exp. Pharmacol. Physiol. 34, 1037-1043 (2007).
29. Surekha RH, Srikanth BB, Jharna P et al.: Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med. J. 48, 137-142 (2007).
30. Reckelhoff JF: Gender differences in the regulation of blood pressure. Hypertension 37, 1199-1208 (2001).
31. Sieveking DP, Chow RW, Ng MK: Androgens, angiogenesis and cardiovascular regeneration. Curr. Opin. Endocrinol. Diabetes Obes. 17(3), 277-283 (2010).
32. Vitale C, Fini M, Speziale G, Chierchia S: Gender differences in the cardiovascular effects of sex hormones. Fundam. Clin. Pharmacol. (2010) (Epub ahead of print).
33. Jankord R, Turk JR, Schadt JC et al.: Sex difference in link between interleukin-6 and stress. Endocrinology 148, 3758-3764 (2007).
34. Lee CE, McArdle A, Griffths RD: The role of hormones, cytokines and heat shock proteins during age-related muscle loss. Clin. Nutr. 26, 524-534 (2007).
35. Yeun JY, Kaysen GA: C-reactive protein, oxidative stress, homocysteine, and troponin as infammatory and metabolic predictors of atherosclerosis in ESRD. Curr. Opin. Nephrol. Hypertens. 9, 621-630 (2000).
36. Cooper SA, Whaley-Connell A, Habibi J et al.: Renin-angiotensin- aldosterone system and oxidative stress in cardiovascular insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 293, H2009-H2023 (2007).
37. Leiter LA, Lewanczuk RZ: Of the renin- angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am. J. Hypertens 18, 121-128 (2005).
38. Sander K, Horn CS, Briesenick C, Sander D: High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE Study. Stroke 38, 2881-2886 (2007).
39. Andersson L, Preda I, Hahn-Zoric M et al.: Urinary proteins in children with urinary tract infection. Pediatr. Nephrol. 24, 1533-1538 (2009).
40. Chait A, Han CY, Oram JF, Heinecke JW: Thematic review series: the immune system and atherogenesis. Lipoprotein-associated infammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res. 46, 389-403 (2005).
41. Erben J, Panacek V, Prochazka J, Stambergova H: [C-reactive protein in diagnosis of complications in renal insuffciency and failure]. Vnitr. Lek. 50, 497-502 (2004).
42. Galloway A, Green HT, Windsor JJ et al.: Serial concentrations of C-reactive protein as an indicator of urinary tract infection in patients with spinal injury. J. Clin. Pathol. 39, 851-855 (1986).
43. Pepys MB, Hirschfeld GM: C-reactive protein: a critical update. J. Clin. Invest. 111, 1805-1812 (2003).
44. Singh U, Devaraj S, Jialal I: C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin. Chem. 55, 361-364 (2009).
45. Klebanoff SJ: Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77, 598-625 (2005).
46. Matthijsen RA, Huugen D, Hoebers NT et al.: Myeloperoxidase is critically involved in the induction of organ damage after renal ischemia reperfusion. Am. J. Pathol. 171, 1743-1752 (2007).
47. Wu CC, Chen JS, Wu WM et al.: Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol. Dial. Transplant 20, 1134-1139 (2005).
48. Wu AH: Novel biomarkers of cardiovascular disease: myeloperoxidase for acute and/or chronic heart failure? Clin. Chem. 55, 12-14 (2009).
49. Zhang C, Yang J, Jacobs JD, Jennings LK: Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. Am. J. Physiol. Heart Circ. Physiol. 285, H2563-H2572 (2003).